Skip to main content

Market Authorization of First R21 Malaria Vaccines in Ghana

The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.

To read the full article, click here

Other related documents see below.

R21 Malaria
R21 Malaria vaccine